• Protease Inhibitor Cocktail for OXPHOS Assays

  2026-09-02

  Protect LRPPRC, oxidative phosphorylation proteins, and labile complexes from degradation during cell and tissue extraction. This EDTA-free, DMSO-based formulation is especially useful for Western blotting, co-immunoprecipitation, pull-down, and kinase workflows where metal chelation could compromise the assay.

• HyperPFU™ High-Fidelity DNA Polymerase Guide

  2026-09-01

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suitable for blunt-ended cloning and sequencing workflows, but not for protocols that depend on 3′-A overhangs or preformed sticky ends.

• Magneto-Piezoelectric Scaffolds for Infectious Bone Repair

  2026-09-01

  This ACS Nano study develops a dual-responsive, 3D-printed scaffold that combines biofilm disruption with targeted immune and bone-regeneration support. Its central mechanistic finding is that activating oxidative phosphorylation in Icam1+ macrophages through JAK2-STAT3 signaling can promote a pro-reparative immune environment after infection control.

• Protease Inhibitor Cocktail for OXPHOS Assays

  2026-08-31

  Protect LRPPRC and OXPHOS-related proteins during cell and tissue extraction with an EDTA-free, broad-spectrum formulation. This practical guide connects dependable sample preparation with Western blot, co-immunoprecipitation, kinase, and tissue workflows used to investigate LRPPRC–dasatinib synergy.

• Tetrazolium (chloride): Readout Design and Limits

  2026-08-31

  Tetrazolium (chloride), also called Tetrazolium Red, converts dehydrogenase activity into a spatial and spectrophotometric formazan signal. This guide explains how to interpret that signal, design tissue and cell assays, and avoid confusing metabolic activity with complete cellular viability.

• Dronedarone in AF Assay Design

  2026-08-30

  Dronedarone (Multaq) is more than a broad-spectrum antiarrhythmic reference compound. This guide shows how its ion-channel profile, KCa2 assay evidence, solvent behavior, and CYP liabilities can inform rigorous atrial fibrillation treatment research.

• Rapamycin in Candida Biofilm Autophagy Assays

  2026-08-29

  Explore how Rapamycin (Sirolimus) can function as a mechanistic perturbation in Candida albicans biofilm research. This guide connects FKBP12–mTOR biology with PP2A-dependent autophagy, drug resistance, and practical assay controls.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-08-28

  The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that links trophoblast ferroptosis, iron handling, and syncytialization defects in preeclampsia. Its combination of O-GlcNAc modification proteomics, trophoblast stress models, and in vivo pregnancy analysis provides a mechanistic framework for studying placental oxidative injury.

• Antiarrhythmic Drugs at KCa2 Channels in AF

  2026-08-28

  The reference study used automated whole-cell patch clamp to test whether established antiarrhythmic drugs directly inhibit human KCa2.2 and KCa2.3 channels, an atrial-enriched target under investigation for atrial fibrillation treatment research. Dronedarone showed no clinically relevant KCa2 inhibition under the tested conditions, while dofetilide and propafenone produced inhibition only at concentrations substantially above their free therapeutic plasma levels.

• Protease and Phosphatase Inhibitor Cocktail Workflow

  2026-08-27

  Protect protein abundance and phosphorylation states during hPSC-cardiomyocyte lysis, especially when comparing right ventricular-like and left ventricular-like phenotypes. This EDTA-free, 100X format also supports flexible extraction workflows where metal chelation could compromise downstream assays.

• Toremifene for Breast Cancer: 20 Years of Evidence

  2026-08-27

  This review synthesizes two decades of clinical and pharmacologic evidence for toremifene as an endocrine option in postmenopausal breast cancer. Its main contribution is a balanced interpretation of efficacy, safety, tissue-selective estrogen activity, pharmacokinetic differences from tamoxifen, and the treatment-selection implications of aromatase inhibitors.

• TH287 MTH1 Inhibitor for Cancer Radiosensitization

  2026-08-26

  TH287 turns oxidized nucleotide stress into a testable vulnerability and offers a practical way to optimize radiosensitization in castration-resistant prostate cancer models. The strongest reference-study effect emerged when irradiation followed inhibitor exposure by 12 hours, making treatment sequence as important as compound concentration.

• FPH1 (BRD-6125) for Functional Hepatocytes

  2026-08-26

  FPH1 (BRD-6125) supports expansion of functional human hepatocytes while preserving decision points for albumin, CYP3A4, and AFP assessment. This guide translates the compound into practical primary-cell and iPS-derived hepatocyte workflows, with troubleshooting strategies and a carefully bounded connection to light-regulated gene-expression research.

• LY294002 Workflows for PI3K Signaling Studies

  2026-08-25

  LY294002 enables time-resolved interrogation of PI3K/Akt/mTOR signaling, apoptosis, autophagy, and tumor–macrophage crosstalk. This practical guide connects reversible pathway inhibition with SPP1-driven ESCC biology, while emphasizing controls for dose, timing, and off-target interpretation.

• Taxus chinensis Fruit, TLR4, and Neuroinflammation

  2026-08-25

  A 2025 Journal of Ethnopharmacology study integrated aging-model behavior, oxidative-stress profiling, BV2 microglia experiments, UPLC-MS/MS, and molecular docking to investigate how Taxus chinensis fruit extract affects neuroinflammation. The findings associate the extract with reduced microglial activation and suppression of the TLR4/NF-κB/NLRP3 axis, while also showing why direct target-validation studies remain necessary.

8084 records 3/539 page Previous Next 12345 下5页 Last page